Global prevalence of non-alcoholic fatty liver disease (NAFLD) is 25.24% in 2016, a percentage that has rapidly increased over the past decade.
There exist two types of NAFLD, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Both Masson’s Trichrome Analysis CD45/ CD138/ Adipophilin IHC subtypes are associated with lipid accumulation in the liver, the latter being more severe with inflammatory cell infiltration, fibrosis and subsequent hepatocyte damage and impaired organ function.